Effect of selenium supplementation and source on the selenium status of horses

This study was conducted to determine the effect of Se supplementation and source on the Se status of horses. Eighteen 18-mo-old nonexercised horses were randomly assigned within sex to 1 of 3 treatments: 1) control (CTRL, no supplemental Se, 0.15 mg of Se/kg of total diet DM); 2) inorganic Se (INORG, CTRL + 0.45 mg of Se/kg of total diet DM from NaSeO3); or organic Se [ORG, CTRL + 0.45 mg of Se/kg of total diet DM from zinc-L-selenomethionine (Availa Se, Zinpro, Corp., Eden Prairie, MN)]. Horses were acclimated to the CTRL diet (7.1 kg of DM alfalfa hay and 1.2 kg of DM concentrate per horse daily) for 28 d. After the acclimation period, the appropriate treatment was top-dressed on the individually fed concentrate for 56 d. Jugular venous blood samples were collected on d 0, 28, and 56. Middle gluteal muscle biopsies were collected on d 0 and 56. Muscle and plasma were analyzed for Se concentrations. Glutathione peroxidase activity was measured in muscle (M GPx-1), plasma (P GPx-3), and red blood cells (RBC GPx-1). Data were analyzed as a repeated measures design. Mean plasma Se concentration on d 28 and 56 was greater (P < 0.05) for Se-supplemented horses compared with CTRL horses, and tended (P < 0.1) to be greater in ORG vs. INORG on d 28. Mean muscle Se concentration and P GPx-3 activities increased (P < 0.05) from d 0 to 56 but were not affected by treatment. Mean RBC GPx-1 activity tended to be greater (P < 0.1) in ORG than INORG or CTRL horses on d 28, and tended to be greater (P < 0.1) for INORG compared with ORG horses on d 56. Mean RBC GPx-1 activity of INORG and ORG horses was not different from that of CTRL on d 56. Mean M GPx-1 activity decreased (P < 0.01) from d 0 to 56. In conclusion, zinc-L-selenomethionine was more effective than NaSeO3 at increasing plasma Se concentration from d 0 to 28; however, both supplemental Se sources had a similar effect by d 56. No difference in Se status due to Se supplementation or source could be detected over a 56-d supplementation period by monitoring middle gluteal muscle Se, M GPx-1, or P GPx-3. Results for RBC GPx-1 also were inconclusive relative to the effect of Se supplementation and source.     

The effect of injectable barium selenate on the selenium status of horses on pasture

AIM: To examine the effect of intramuscular barium selenate on the blood selenium concentration of horses with marginal selenium status. METHODS: Eighteen mares were assigned to one of six groups. The mares in groups 1-4 received barium selenate at 0.5, 0.75, 1.0 and 1.5 mg Se/kg, respectively, injected into the right pectoral muscle mass. The mares in group 5 received sodium selenate at 0.05 mg Se/kg orally at 8-week intervals. The mares in group 6 were left untreated. Blood samples were collected at 0, 1, 2, 5, 10, 30, 60, 90, 120, 180, 240, 300 and 360 days after the initial treatment for assay of whole blood and plasma selenium. Injection site reactions were recorded on each sampling date. RESULTS: Treatment with barium selenate at each dose rate significantly increased whole blood, plasma and blood cell selenium concentrations when compared to no treatment or oral treatment with sodium selenate, and maintained group mean whole blood selenium concentrations in the adequate range (>1600 nmol/l) until the end of the experimental period of 1 year. The severity of injection site reactions increased with dose rate but was considered acceptable alt the lower dose rates used. CONCLUSION: The injection of barium selenate placed aseptically at a deep intramuscular site was efficacious in correcting the selenium status of mares grazing pasture with a selenium content of 0.01-0.07 mg/kg DM. However, some swelling and fibrosis at the injection site was apparent at all dose rates used. CLINICAL RELEVANCE: There is currently no long-acting selenium supplementation product licensed in New Zealand for use in horses. Barium selenate promises to provide a useful method for selenium supplementation for horses, with an effective duration of at least 1 year following a single injection.     

Effect of selenium source and dose on selenium status of mature horses

This study was conducted to determine the effects of either dietary Se source or dose on the Se status of horses. Twenty-five mature horses were blocked by BW and randomly allocated to 1 of 5 dietary treatments that comprised the same basal diet that differed only in Se source or dose. Treatments were as follows: negative control (0.085 mg of Se/kg of DM), 3 different dietary concentrations of supplemental organic Se (Se yeast; 0.2, 0.3, and 0.4 mg of total Se/kg of DM), and positive control (0.3 mg of total Se/kg of DM) supplemented with Na selenite. Horses initially received the control diet (6 kg of grass hay and 3 kg of concentrate per horse daily) for 56 d to allow diet adaptation. After the period of diet adaptation, horses were offered their respective treatments for a continuous period of 112 d. Jugular venous blood samples were collected before the morning feed on d 0, 28, 56, 84, and 112. Whole blood and plasma were analyzed for total Se, glutathione peroxidase activity in whole blood (GPX-1) and plasma, and thyroid hormones (thyroxine and triiodothyronine) in plasma. The proportion of total Se as selenomethionine (SeMet) or selenocysteine in pooled whole blood and plasma samples was determined on d 0, 56, and 112. Data were analyzed as repeated measures. Total Se in blood and plasma and GPX-1 activity were greater in all supplemented horses (P < 0.001, except P < 0.01 for GPX-1 in horses supplemented with the least dose of Se yeast) with a linear dose effect of Se yeast for whole blood and plasma Se (P < 0.001) and a quadratic dose effect (P < 0.05) for whole blood GPX-1 activity. A plateau for total Se in plasma was achieved within 75 to 90 d, although this was not observed in blood total Se or GPX-1 activity. On d 84 and 112, horses supplemented with Se yeast showed greater total Se in blood (P < 0.05) compared with horses supplemented with Na selenite, and a source effect (P < 0.05) was observed in the relationship between total blood Se and GPX-1 activity. Selenocysteine (the predominant form of Se in whole blood and plasma) increased in all horses supplemented with Se. The SeMet content of whole blood and plasma increased in horses supplemented with Se yeast, but it was not observed in those supplemented with selenite. The rate of increase in SeMet over time was greater in whole blood (P < 0.05) and plasma (P = 0.10) with the Se yeast product. In conclusion, Se yeast was more effective than Na selenite in increasing total Se in blood, mainly as consequence of a greater increase of the proportion of Se comprised as SeMet, but it did not modify GPX-1 activity.     

Effects of selenium source on measures of selenium status and immune function in horses

The effects of selenium (Se) supplementation and source on equine immune function have not been extensively studied. This study examined the effects of oral Se supplementation and Se source on aspects of innate and adaptive immunity in horses. Fifteen horses were assigned to 1 of 3 groups (5 horses/group): control, inorganic Se (sodium selenite), organic Se (Se yeast). Immune function tests performed included: lymphocyte proliferation in response to mitogen concanavalin A, neutrophil phagocytosis, antibody production after rabies vaccination, relative cytokine gene expression in stimulated lymphocytes [interferon gamma (IFNγ), interleukin (IL)-2, IL-5, IL-10, tumor necrosis factor alpha (TNFα)], and neutrophils (IL-1, IL-6, IL-8, IL-12, TNFα). Plasma, red blood cell Se, and blood glutathione peroxidase activity were measured. Plasma and red blood cell Se were highest in horses in the organic Se group, compared with that of inorganic Se or control groups. Organic Se supplementation increased the relative lymphocyte expression of IL-5, compared with inorganic Se or no Se. Selenium supplementation increased relative neutrophil expression of IL-1 and IL-8. Other measures of immune function were unaffected. Dietary Se content and source appear to influence immune function in horses, including alterations in lymphocyte expression of IL-5, and neutrophil expression of IL-1 and IL-8.     

Cadmium and selenium levels in kidneys from Danish horses

The content of cadmium and selenium in horse kidneys from Jutland , Denmark, in relation to age, local geographical variation and possible relationship between the two elements has been investigated. During the winter of 1982-1983 kidneys from 50 horses were sampled and analysed for cadmium and selenium. The cadmium content of the horse kidneys was recorded in connection with the age of the horses. The cadmium level increases until the animal has reached approximately 7 years of age. At this age the cadmium concentration levels off. A significant regional difference was shown. The cadmium content is higher in horse kidneys from South and Central Jutland than in kidneys from North Jutland (Fig. 2). This geographic pattern is consistent with the one for atmospheric deposition of cadmium and cadmium content in Danish cattle kidneys from Jutland . The cadmium level in kidneys from Danish horses is considerably lower than the level in Norwegian and Swedish horse kidneys. Differences in water hardness and atmospheric deposition may explain some of this difference within Scandinavian countries. The selenium concentration shows no relationship with neither age, cadmium content nor place of rearing. So, the study did not reveal any relationship between the cadmium and selenium concentrations in horse kidneys. The high level of cadmium found in Danish horse kidneys emphasizes the importance of a prohibition against the use of the kidneys in animal and human nutrition, as proposed by others.     

Bioavailability and pharmacokinetics of metronidazole in fed and fasted horses

Britzi, M., Gross, M., Lavy, E., Soback, S., Steinman, A. Bioavailability and pharmacokinetics of metronidazole in fed and fasted horses. J. vet. Pharmacol. Therap. 33 , 511–514. Metronidazole (1‐[2‐hydroxyethyl]‐2‐methyl‐5‐nitroimidazole) is a bactericidal antimicrobial agent used for treatment of infectious diseases caused by anaerobic bacteria and protozoa. Pharmacokinetics of metronidazole following its administration to horses was previously described ( Sweeney et al., 1986 ; Baggot et al., 1988 ; Specht et al., 1992 ; Steinman et al., 2000 ). The bioavailability (F) was 85% (ranging from 57% to 105%) and the time to reach maximum serum concentration (t_max) was 1–2 h after oral dose at 25 mg/kg body weight ( Sweeney et al., 1986 ). Baggot et al. (1988) found that F was 74.5% (ranging from 58.4% to 91.5%) and t_max was 1.5 h after oral dose at 20 mg/kg body weight. Specht et al. (1992) reported that F was 97% (ranging from 79% to 111%) and t_max was 40 min after oral dose at 15 mg/kg body weight. In an earlier study by our group F was 74% and t_max was 65 min after oral dose at 20 mg/kg body weight ( Steinman et al., 2000 ). These individual variations in F might be partially explained by the effect of feed, among other factors, mainly on metronidazole absorption. Interactions between food and drugs may reduce or increase the drug effect. The majority of clinically relevant food–drug interactions are caused by food‐induced changes on the bioavailability of the drug ( Schmidt & Dalhoff, 2002 ). In dogs, absorption of metronidazole is enhanced when given with food, but delayed in humans ( Plumb, 1995 ). Although, metronidazole is used commonly to treat various clinical conditions in horses with relatively little adverse effects ( Sweeney et al., 1991 ), narrow margin of safety was suggested because histological evidence of peripheral neurotoxicity and hepatotoxicity were noted in horses treated with doses as low as 30 mg/kg body weight every 12 h orally for 30 days ( White et al., 1996 ). For drugs with a narrow therapeutic index, even small changes in dose–response effects can have significant consequences ( Schmidt & Dalhoff, 2002 ).     

Pharmacokinetics and diuretic effect of bumetanide following intravenous and intramuscular administration to horses

Concentrations of the potent diuretic bumetanide were determined by a sensitive high performance liquid chromatographic procedure in plasma and urine from horses following intravenous and intramuscular administration of a dose rate of 15 micrograms/kg. The elimination half-life was found to be 6.3 min, the volume of distribution at steady state 68 ml/kg and the total plasma clearance 10.9 ml/min/kg. The onset of diuresis occurred within 15 min and diuresis was no longer apparent 1 h after i.v. administration. Given by the intramuscular (i.m.) route, bumetanide was rapidly absorbed; bioavailability was 70-80%. i.m. administration of bumetanide prolonged its plasma half-life (11-27 min) and enhanced and prolonged its diuretic effect.     

Comparative efficacy, persistent effect, and treatment intervals of anthelmintic pastes in naturally infected horses.

Eighty horses were involved in a comparative, controlled, and randomised field study conducted in Australia and Brazil. This study was undertaken to address the duration of efficacy (by faecal egg count reduction) of four anthelmintic pastes and to measure the time required between treatments on horses naturally infected by gastrointestinal nematodes. The treatment interval was based on the egg reappearance period (ERP), defined as "the period after treatment when horses have reached a positive egg count equal or superior to 200 eggs per gram (epg) of faeces". Horses were ranked according to pre-treatment faecal egg counts and randomly allocated on Day 0 to one of the four treatment groups (n=16). Group A received a combination of ivermectin at 200 microg/kg and praziquantel at 1.5mg/kg, Group B received an ivermectin paste at 200 microg/kg, Group C received a reference product containing ivermectin at 200 microg/kg, Group D received a moxidectin paste at 400 microg/kg, and Group E received a placebo. Horses were individually faecal sampled at weekly interval from Days 0 to 70 after treatment and coprocultures were made on pooled samples at the pre-treatment time on D-7 in Brazil and D-6 in Australia.The nematode population was mainly composed of small strongyles (Cyathostominae, Gyalocephalus spp., Triodontophorus spp.). All products were efficient (>90% efficacy) until Day 42 with no statistical difference between groups. From Day 49 onwards, Group C reached the threshold, while Group B exceeded this threshold on Day 56. Groups A and D remained below 200 epg for the entire study period (70 days). The interval between two anthelmintic treatments can vary according to the threshold. The ERP was defined as the period after treatment while the output of eggs is negligible or considered as acceptable. The mean number of days calculated to recurrence of 200 epg and more was, respectively, 60 days for product A, 56 days for products B and C, and 64 days for product D. If treatments are combined with other methods of limiting exposure to infective larvae on pasture, the number of treatments required will be reduced even further.     

Plasma concentrations of endothelin-like immunoreactivity in healthy horses and horses with naturally acquired gastrointestinal tract disorders

OBJECTIVE: To compare plasma endothelin (ET)- like immunoreactivity between healthy horses and those with naturally acquired gastrointestinal tract disorders. ANIMALS: 29 healthy horses and 142 horses with gastrointestinal tract disorders. PROCEDURE: Blood samples were collected from healthy horses and from horses with gastrointestinal tract disorders prior to treatment. Magnitude and duration of abnormal clinical signs were recorded, and clinical variables were assessed via thorough physical examinations. Plasma concentrations of ET-like immunoreactivity were measured by use of a radioimmunoassay for human endothelin-1, and CBC and plasma biochemical analyses were performed. RESULTS: Plasma ET-like immunoreactivity concentration was significantly increased in horses with gastrointestinal tract disorders, compared with healthy horses. Median plasma concentration of ET-like immunoreactivity was 1.80 pg/ml (range, 1.09 to 3.2 pg/ml) in healthy horses. Plasma ET-like immunoreactivity was greatest in horses with strangulating large-intestinal obstruction (median, 10.02 pg/ml; range, 3.8 to 22.62 pg/ml), peritonitis (9.19 pg/ml; 789 to 25.83 pg/ml), and enterocolitis (8.89 pg/mI; 6.30 to 18.36 pg/ml). Concentration of ET-like immunoreactivity was significantly associated with survival, PCV, and duration of signs of pain. However, correlations for associations with PCV and duration of pain were low. CONCLUSIONS AND CLINICAL RELEVANCE: Horses with gastrointestinal tract disorders have increased plasma concentrations of ET-like immunoreactivity, compared with healthy horses. The greatest values were detected in horses with large-intestinal strangulating obstructions, peritonitis, and enterocolitis. This suggests a potential involvement of ET in the pathogenesis of certain gastrointestinal tract disorders in horses.     

African horse sickness in naturally infected,immunised horses

To determine whether subclinical cases, together with clinical cases, of African horse sickness (AHS) occur in immunised horses in field conditions, whole blood samples were collected and rectal temperatures recorded weekly from 50 Nooitgedacht ponies resident in open camps at the Faculty of Veterinary Science, University of Pretoria, Onderstepoort, during 2008–2010. The samples were tested for the presence of African horse sickness virus (AHSV) RNA by a recently developed real‐time RT‐PCR. It was shown that 16% of immunised horses in an AHS endemic area were infected with AHSV over a 2 year period, with half of these (8%) being subclinically infected. The potential impact of such cases on the epidemiology of AHS warrants further investigation.     

Blood buffering in sedentary miniature horses after administration of sodium bicarbonate in single doses of varying amounts

Blood acid-base and electrolyte status was studied in four sedentary Miniature Horses treated with 200, 300, 400 and 500 mg of sodium bicarbonate (NaHCO₃) per kg of body weight (BW). Arterial blood was collected before treatment with NaHC0₃ and each hour for 5 h after treatment. All treatments resulted in an increase in blood pH, bicarbonate (HCO₃⁻) concentration and base excess (BE) by 1 h post-dosage, which continued through the 5th hour (P < .05). Treatment with 200 mg NaHC0₃/kg BW resulted in less elevated blood HCO₃⁻ concentrations (P < .03) and BE values (P < .01) when compared to the other treatments. Following dosing with NaHCO₃, plasma Na⁺ concentrations increased among all treatments but declined to initial values by 3 h post-treatment. The 200 mg NaHCO₃/kg BW dosage resulted in the smallest increases in plasma Na⁺ concentrations (P < .03). Both plasma K⁺ and Ca⁺⁺ concentrations were lower (P < .05) among all treatment groups 1 h post-dosage but returned to initial values by 5 h and 3 h posttreatment, respectively, with no differences (P >.05) among treatments. All NaHCO₃ dosages increased blood buffering capacity as indicated by increased blood pH, HCO₃⁻ concentration and BE. Maximum blood pH, HCO⁻₃ concentration and BE was reached using a dosage of 300 mg NaHCO₃/kg BW. Also, all treatments altered the plasma electrolyte concentrations.     

The levels of zearalenone and its metabolites in plasma,urine and faeces of horses fed with naturally,Fusarium toxin–contaminated oats

Concentration profile of zearalenone (ZON) and its metabolites in plasma, urine and faeces samples of horses fed with Fusarium toxin–contaminated oats is described. In plasma, β‐zearalenol (β‐ZOL) was detected at high levels on day 10 of the study (3.21–6.24 μg/l). β‐Zearalenol and α‐zearalenol were the major metabolites in urine. Zearalenone, α‐ZOL and β‐ZOL were predominantly found in faeces. Zearalanone could also be detected in urine (1.34–5.79 μg/l) and faeces (1 μg/kg). The degree of glucuronidation was established in all sample types, approximately 100% in urine and plasma. Low per cent of glucuronidation (4–15%) was found in faeces samples. The results indicate the main conversion of ZON into β‐ZOL in horse. This finding could explain why horse is not susceptible to ZON in comparison with swine which produce α‐ZOL as a predominant metabolite.